CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: TRPV1 (ImmuneEditome ID:7442)

1. Gene summary of enriched editing regions for TRPV1

check button Gene summary
Gene informationGene symbol

TRPV1

Gene ID

7442

GeneSynonymsVR1
GeneCytomap

17p13.2

GeneTypeprotein-coding
GeneDescriptiontransient receptor potential cation channel subfamily V member 1|OTRPC1|capsaicin receptor|osm-9-like TRP channel 1|transient receptor potential vanilloid 1a|transient receptor potential vanilloid 1b|vanilloid receptor subtype 1
GeneModificationdate20230530
UniprotIDQ8NER1;E7EQ78;I3L1R6;A0A3B3ISI9;E7ESJ2
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr17:3597736-3597941:-ENST00000572705.1ENSG00000262304.1TRPV1intronicAluSg4chr17:3597736-3597941:-.alignment
chr17:3597736-3597941:-ENST00000572919.1ENSG00000262304.1TRPV1intronicAluSg4chr17:3597736-3597941:-.alignment
chr17:3599676-3600380:-ENST00000572705.1ENSG00000262304.1TRPV1intronicAluSx3,L1MB3,AluSgchr17:3599676-3600380:-.alignment
chr17:3599676-3600380:-ENST00000572919.1ENSG00000262304.1TRPV1intronicAluSx3,L1MB3,AluSgchr17:3599676-3600380:-.alignment
chr17:3605242-3609184:-ENST00000572705.1ENSG00000262304.1TRPV1splicingTigger7,AluSx1,MIR,(TTTA)n,MLT1I,AluSz6,AluSx,MER44Dchr17:3605242-3609184:-.alignment


Top

2. Tumor-specific enriched editing regions for TRPV1


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
ENSG00000262304.1,TRPV1BRCAEAG1.3473e-04image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for TRPV1


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for TRPV1


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000262304.1,TRPV1
OVEAGIRENSG00000162227.3chr1162782112:62782333:62782692:627828250.34961.6935e-044.6544e-110.4398imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CSTF2T;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDF1;ZNF184NAMacrophages_M0GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000262304.1,TRPV1
OVEAGIRENSG00000147144.8chrX49064369:49064664:49065035:490650980.32017.0706e-045.9407e-090.4035imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28B;LSM11;METTL3;MOV10;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDF1;ZNF184NAMacrophages_M0GSVA_HALLMARK_HEME_METABOLISM
ENSG00000262304.1,TRPV1
OVEAGIRENSG00000131584.14chr11298566:1299356:1299830:12999050.29339.2535e-048.6616e-080.4009imageNACIN1;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RBM6;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDF1;ZNF184NAMacrophages_M1GSVA_HALLMARK_HEME_METABOLISM
ENSG00000262304.1,TRPV1
OVEAGIRENSG00000035862.8chr1778852976:78855864:78855963:788560070.28081.0113e-036.5936e-090.4398imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;LIN28;LIN28B;MBNL2;METTL3;MOV10;MSI1;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM6;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TRA2A;U2AF1;U2AF2;UPF1;YTHDF1;ZC3H7B;ZNF184TIMP2Macrophages_M1GSVA_HALLMARK_GLYCOLYSIS
ENSG00000262304.1,TRPV1
OVEAGIRENSG00000170291.10chr177258587:7258720:7258825:7258926-0.18902.4166e-033.9832e-09-0.4299imageNAIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS2;KHSRP;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDF1;ZC3H7B;ZNF184NAGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
ENSG00000262304.1,TRPV1
OVEAGIRENSG00000101246.15chr2063699123:63700530:63700601:637007020.29724.0504e-035.8382e-100.4146imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CNBP;CSTF2T;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28B;LSM11;MOV10;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDF1;ZNF184NAMacrophages_M0GSVA_HALLMARK_COAGULATION
ENSG00000262304.1,TRPV1
OVEAGIRENSG00000095319.10chr9128994372:128994442:128994855:1289948900.28456.2136e-033.0488e-090.4028imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS2;KHSRP;LIN28;LIN28B;LSM11;MBNL2;METTL3;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RBM6;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDF1;ZC3H7B;ZNF184NAT_cells_gamma_deltaGSVA_HALLMARK_APICAL_JUNCTION
ENSG00000262304.1,TRPV1
OVEAGIRENSG00000120899.13chr827430875:27431016:27431397:274314720.21383.1300e-021.2555e-070.4008imageNACIN1;ADAR;BUD13;CELF2;CNBP;CSTF2T;DDX54;DGCR8;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI1;NONO;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBFOX2;RBM27;RNF219;SF3A3;SF3B4;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDF1;ZNF184PTK2BMacrophages_M1GSVA_HALLMARK_UV_RESPONSE_UP

More results



Top

5. Enriched editing regions and immune infiltration for TRPV1


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000262304.1,TRPV1ACCEAGDendritic_cells_resting9.4951e-030.5399image
chr17:3605242-3609184:-BLCAEERDendritic_cells_activated1.6424e-020.3520image
ENSG00000262304.1,TRPV1BLCAEAGDendritic_cells_activated1.7070e-020.3464image
ENSG00000262304.1,TRPV1BRCAEAGNK_cells_activated8.6256e-040.2216image
ENSG00000262304.1,TRPV1CESCEAGT_cells_regulatory_(Tregs)1.3217e-020.3794image
chr17:3605242-3609184:-COADEERDendritic_cells_activated4.3756e-040.5931image
ENSG00000262304.1,TRPV1COADEAGDendritic_cells_activated1.9054e-040.6132image
chr17:3599676-3600380:-ESCAEERT_cells_gamma_delta2.1610e-02-0.3817image
chr17:3605242-3609184:-ESCAEERT_cells_CD4_memory_resting4.0911e-020.2223image
ENSG00000262304.1,TRPV1ESCAEAGT_cells_follicular_helper4.2421e-020.1994image
ENSG00000262304.1,TRPV1GBMEAGEosinophils1.4020e-040.3449image
ENSG00000262304.1,TRPV1KIRCEAGDendritic_cells_activated2.4006e-060.5051image
chr17:3605242-3609184:-KIRPEERT_cells_CD82.0737e-020.3558image
ENSG00000262304.1,TRPV1KIRPEAGT_cells_CD82.8634e-020.3264image
ENSG00000262304.1,TRPV1LGGEAGMacrophages_M21.3047e-02-0.1879image
ENSG00000262304.1,TRPV1LIHCEAGT_cells_regulatory_(Tregs)4.9143e-030.3740image
chr17:3605242-3609184:-LUADEERT_cells_CD4_memory_activated1.0289e-070.6074image
ENSG00000262304.1,TRPV1LUADEAGT_cells_CD4_memory_activated6.2935e-070.5513image
ENSG00000262304.1,TRPV1LUSCEAGMast_cells_activated1.3623e-020.3369image
ENSG00000262304.1,TRPV1OVEAGMacrophages_M19.8291e-03-0.1795image
ENSG00000262304.1,TRPV1PRADEAGDendritic_cells_activated1.0702e-040.3564image
chr17:3605242-3609184:-SKCMEERDendritic_cells_resting4.9708e-020.2290image
ENSG00000262304.1,TRPV1STADEAGB_cells_memory8.6968e-040.2153image
ENSG00000262304.1,TRPV1TGCTEAGMonocytes4.1117e-02-0.2016image
chr17:3605242-3609184:-THCAEERB_cells_naive4.8362e-03-0.2556image
ENSG00000262304.1,TRPV1THCAEAGB_cells_naive4.8414e-03-0.2545image
ENSG00000262304.1,TRPV1THYMEAGDendritic_cells_resting2.0213e-030.5330image
ENSG00000262304.1,TRPV1UCECEAGT_cells_gamma_delta1.3706e-020.3820image


Top

6. Enriched editing regions and immune gene sets for TRPV1


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000262304.1,TRPV1ACCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG3.0635e-02-0.4615image
ENSG00000262304.1,TRPV1BLCAGSVA_HALLMARK_MYC_TARGETS_V2EAG8.8068e-030.3780image
chr17:3605242-3609184:-BLCAGSVA_HALLMARK_MYC_TARGETS_V2EER7.1103e-030.3916image
ENSG00000262304.1,TRPV1BRCAGSVA_HALLMARK_HEME_METABOLISMEAG1.3480e-06-0.3170image
ENSG00000262304.1,TRPV1CESCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG2.7892e-02-0.3394image
ENSG00000262304.1,TRPV1COADGSVA_HALLMARK_P53_PATHWAYEAG1.8272e-03-0.5296image
chr17:3605242-3609184:-COADGSVA_HALLMARK_P53_PATHWAYEER4.7075e-03-0.4943image
chr17:3605242-3609184:-ESCAGSVA_HALLMARK_KRAS_SIGNALING_DNEER2.5995e-03-0.3226image
ENSG00000262304.1,TRPV1ESCAGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG5.3888e-05-0.3852image
ENSG00000262304.1,TRPV1HNSCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG1.5770e-03-0.3961image
ENSG00000262304.1,TRPV1KIRCGSVA_HALLMARK_P53_PATHWAYEAG4.9887e-03-0.3149image
ENSG00000262304.1,TRPV1LGGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.2355e-03-0.2303image
ENSG00000262304.1,TRPV1LIHCGSVA_HALLMARK_MITOTIC_SPINDLEEAG2.6708e-06-0.5854image
chr17:3605242-3609184:-LUADGSVA_HALLMARK_ANGIOGENESISEER2.7867e-04-0.4396image
ENSG00000262304.1,TRPV1LUADGSVA_HALLMARK_ANGIOGENESISEAG1.3623e-04-0.4375image
ENSG00000262304.1,TRPV1LUSCGSVA_HALLMARK_APICAL_JUNCTIONEAG3.2455e-03-0.3970image
ENSG00000262304.1,TRPV1OVGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG1.8535e-06-0.3252image
chr17:3605242-3609184:-OVGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER3.0160e-03-0.2181image
ENSG00000262304.1,TRPV1PCPGGSVA_HALLMARK_APICAL_JUNCTIONEAG4.6692e-020.2916image
ENSG00000262304.1,TRPV1PRADGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.2613e-06-0.4375image
ENSG00000262304.1,TRPV1SARCGSVA_HALLMARK_PROTEIN_SECRETIONEAG4.4782e-02-0.2406image
chr17:3605242-3609184:-SARCGSVA_HALLMARK_PROTEIN_SECRETIONEER3.0446e-02-0.2608image
chr17:3605242-3609184:-SKCMGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER7.6962e-04-0.3825image
ENSG00000262304.1,TRPV1SKCMGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG6.9622e-04-0.3854image
ENSG00000262304.1,TRPV1STADGSVA_HALLMARK_NOTCH_SIGNALINGEAG2.9599e-07-0.3262image
chr17:3605242-3609184:-STADGSVA_HALLMARK_TGF_BETA_SIGNALINGEER2.4677e-03-0.2104image
chr17:3605242-3609184:-TGCTGSVA_HALLMARK_MITOTIC_SPINDLEEER5.8219e-030.2700image
ENSG00000262304.1,TRPV1TGCTGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.1991e-020.2467image
chr17:3605242-3609184:-THCAGSVA_HALLMARK_ANDROGEN_RESPONSEEER5.4716e-05-0.3597image
ENSG00000262304.1,TRPV1THCAGSVA_HALLMARK_ANDROGEN_RESPONSEEAG7.7662e-05-0.3514image
ENSG00000262304.1,TRPV1THYMGSVA_HALLMARK_GLYCOLYSISEAG3.6807e-020.3765image
ENSG00000262304.1,TRPV1UCECGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG2.1650e-02-0.3578image


Top

7. Enriched editing regions and drugs for TRPV1


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000262304.1,TRPV1BLCADMOGEAG5.6995e-040.4838image
chr17:3605242-3609184:-BLCACCT007093EER4.2689e-040.4981image
ENSG00000262304.1,TRPV1CESCAZD.0530EAG3.6893e-03-0.4383image
chr17:3605242-3609184:-COADBMS.509744EER9.6483e-040.5635image
ENSG00000262304.1,TRPV1COADBMS.509744EAG3.9194e-040.5888image
chr17:3605242-3609184:-ESCAABT.888EER1.1824e-02-0.2719image
ENSG00000262304.1,TRPV1ESCAABT.263EAG5.8903e-03-0.2696image
chr17:3599676-3600380:-ESCAGefitinibEER3.5042e-02-0.3574image
ENSG00000262304.1,TRPV1GBMBMS.754807EAG6.8024e-03-0.2489image
ENSG00000262304.1,TRPV1HNSCBI.D1870EAG1.7658e-04-0.4623image
ENSG00000262304.1,TRPV1KIRCJNK.9LEAG3.7600e-050.4489image
ENSG00000262304.1,TRPV1LGGAS601245EAG1.7908e-040.2804image
ENSG00000262304.1,TRPV1LIHCA.770041EAG1.0578e-03-0.4930image
chr17:3605242-3609184:-LUADLFM.A13EER6.4049e-030.3374image
ENSG00000262304.1,TRPV1LUADLFM.A13EAG4.5427e-030.3330image
ENSG00000262304.1,TRPV1LUSCAICAREAG1.7565e-030.4197image
ENSG00000262304.1,TRPV1OVBicalutamideEAG5.8914e-030.1912image
chr17:3599676-3600380:-OVErlotinibEER5.5794e-030.4110image
chr17:3605242-3609184:-OVKIN001.135EER5.0818e-030.2063image
ENSG00000262304.1,TRPV1PCPGLapatinibEAG7.1672e-03-0.3872image
ENSG00000262304.1,TRPV1PRADATRAEAG8.9870e-06-0.4042image
chr17:3605242-3609184:-SARCCCT018159EER3.9624e-02-0.2483image
ENSG00000262304.1,TRPV1SARCCCT018159EAG3.5480e-02-0.2518image
ENSG00000262304.1,TRPV1SKCMErlotinibEAG7.1234e-04-0.3873image
chr17:3605242-3609184:-SKCMErlotinibEER5.3733e-04-0.3953image
chr17:3605242-3609184:-STADCamptothecinEER1.4583e-02-0.1704image
ENSG00000262304.1,TRPV1STADAG.014699EAG3.8132e-04-0.2294image
chr17:3605242-3609184:-TGCTBryostatin.1EER1.4804e-040.3653image
ENSG00000262304.1,TRPV1TGCTBryostatin.1EAG9.8823e-050.3742image
chr17:3605242-3609184:-THCAAMG.706EER1.1809e-05-0.3882image
ENSG00000262304.1,TRPV1THCAAMG.706EAG1.7256e-05-0.3799image
ENSG00000262304.1,TRPV1THYMGSK269962AEAG1.0035e-02-0.4554image
chr17:3605242-3609184:-UCECJNK.9LEER3.6233e-040.5486image
ENSG00000262304.1,TRPV1UCECMidostaurinEAG1.0121e-020.3972image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType
chr17:3597736-3597941:-ENST00000572705.1Q8NER1DB00132alpha-Linolenic acidSmallMoleculeDrug
chr17:3597736-3597941:-ENST00000572705.1Q8NER1DB00159IcosapentSmallMoleculeDrug
chr17:3597736-3597941:-ENST00000572705.1Q8NER1DB00193TramadolSmallMoleculeDrug
chr17:3597736-3597941:-ENST00000572705.1Q8NER1DB00316AcetaminophenSmallMoleculeDrug
chr17:3597736-3597941:-ENST00000572705.1Q8NER1DB01744CamphorSmallMoleculeDrug
chr17:3597736-3597941:-ENST00000572705.1Q8NER1DB06774CapsaicinSmallMoleculeDrug
chr17:3597736-3597941:-ENST00000572705.1Q8NER1DB09061CannabidiolSmallMoleculeDrug
chr17:3597736-3597941:-ENST00000572705.1Q8NER1DB09120ZucapsaicinSmallMoleculeDrug
chr17:3597736-3597941:-ENST00000572705.1Q8NER1DB11131Capsicum oleoresinBiotechDrug
chr17:3599676-3600380:-ENST00000572705.1Q8NER1DB00132alpha-Linolenic acidSmallMoleculeDrug
chr17:3599676-3600380:-ENST00000572705.1Q8NER1DB00159IcosapentSmallMoleculeDrug
chr17:3599676-3600380:-ENST00000572705.1Q8NER1DB00193TramadolSmallMoleculeDrug
chr17:3599676-3600380:-ENST00000572705.1Q8NER1DB00316AcetaminophenSmallMoleculeDrug
chr17:3599676-3600380:-ENST00000572705.1Q8NER1DB01744CamphorSmallMoleculeDrug
chr17:3599676-3600380:-ENST00000572705.1Q8NER1DB06774CapsaicinSmallMoleculeDrug
chr17:3599676-3600380:-ENST00000572705.1Q8NER1DB09061CannabidiolSmallMoleculeDrug
chr17:3599676-3600380:-ENST00000572705.1Q8NER1DB09120ZucapsaicinSmallMoleculeDrug
chr17:3599676-3600380:-ENST00000572705.1Q8NER1DB11131Capsicum oleoresinBiotechDrug
chr17:3605242-3609184:-ENST00000572705.1Q8NER1DB00132alpha-Linolenic acidSmallMoleculeDrug
chr17:3605242-3609184:-ENST00000572705.1Q8NER1DB00159IcosapentSmallMoleculeDrug
chr17:3605242-3609184:-ENST00000572705.1Q8NER1DB00193TramadolSmallMoleculeDrug
chr17:3605242-3609184:-ENST00000572705.1Q8NER1DB00316AcetaminophenSmallMoleculeDrug
chr17:3605242-3609184:-ENST00000572705.1Q8NER1DB01744CamphorSmallMoleculeDrug
chr17:3605242-3609184:-ENST00000572705.1Q8NER1DB06774CapsaicinSmallMoleculeDrug
chr17:3605242-3609184:-ENST00000572705.1Q8NER1DB09061CannabidiolSmallMoleculeDrug
chr17:3605242-3609184:-ENST00000572705.1Q8NER1DB09120ZucapsaicinSmallMoleculeDrug
chr17:3605242-3609184:-ENST00000572705.1Q8NER1DB11131Capsicum oleoresinBiotechDrug